Please note that assistive links (commonly known as "skip to links") are used throughout this site. These links are not well-supported by some mobile devices. If you are encountering difficulty using these links, please navigate around these links, or access the site on a desktop browser.
Skip to the primary content of this page Skip to the footer of this page
Provident Healthcare Partners Provident Healthcare Partners

Q4 2023 Pharma Services Update

Provident Healthcare Partners
Skip to the end of the Expertise Menu

Q4 2023 Pharma Services Update

M&A activity in pharma services displayed strong resiliency in Q4-23, fueled by platform investments and dozens of add-on acquisitions. Investors remain attracted to the long-term tailwinds driving increasing usage of outsourced services by pharma sponsors and CROs. Sponsors and CROs serve as a well-capitalized customer base and they continue to outsource service lines in order reduce costs, utilize new technologies, and access value added specialty services.

Large pharma services conglomerates continue to diversify their service offerings to de-risk revenue concentration and become more full-service solutions for their clients and patients.

Provident expects pharma services M&A activity to remain strong in 2024 as companies look to fill the potential growth gap from the $100B in patents set to expire by 2030, and PE sponsors begin to exit more mature portfolio companies.

To print and download the full Pharma Services Update report, please click below…

[holo_button icon=”/wp-content/uploads/2024/01/Q4-2023-Pharma-Services-Newsletter.pdf” color=”#003561″ target=”blank”]PRINT/DOWNLOAD[/holo_button]